Drug Trial Radar · NCT02935530
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Last checked: Nov 20, 2026Latest source record: May 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
315
Actual
Start
Jan 2016
Primary completion
Aug 2017
Study completion Oct 2017
Sponsor
- Lead sponsor
- Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 16 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality in women undergoing surgery for gynecologic malignancies. Although the benefit of thromboprophylaxis in reduction of post-operative VTE events after surgery for gynecologic cancers has been well documented around the world, the evidence for Chinese women is rare. The investigators designed this prospective and randomized study to assess the benefit of pharmacologic prophylaxis for patients received surgical treatment for gynecologic malignancies in China.
Conditions
- Gynecologic Neoplasms
- Venous Thromboembolism
- Low Molecular Weight Heparin
- Argatroban
Interventions
s-LMWHDrug
2125KU, subcutaneous injection of 5-10 days
LMWHDrug
4250KU, subcutaneous injection of 5-10 days
ArgatrobanDrug
20mg, injection for 5-10 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- VTE rateTime frame: 30-days from the date of operation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.